Skip to search boxSkip to navigationSkip to main content

The retinoid X receptor: a nuclear receptor that modulates the sleep-wake cycle in rats

  • ,
  • Diana Millán-Aldaco
    ,
  • Gloria Arankowsky-Sandoval
    ,
  • Tetsuya Yamamoto
    ,
  • Luis Cid
    ,
  • Diogo Monteiro
  • ,
  • Intercontinental Neuroscience Research Group
    ,
  • Universidad Nacional Autónoma de México
    ,
  • Universidad Autonoma de Yucatan
    ,
  • Tokushima University
    ,
  • Universidade de Trás-os-Montes e Alto Douro
Research Output: Contribution to journal Article Peer-review

Open access

Publication Information

Output type

Research Output: Contribution to journal Article Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 2055-2073 (19 pages)

Journal (Volume, Issue Number)

Psychopharmacology (Volume 237, Issue 7)

Publication milestones

  • Published - 01/07/2020

Publication status

Published - 01/07/2020

ISSN

0033-3158

Publication IDs

  • Scopus: 85085749053
  • PubMed: 32472163

Abstract

Rationale: The nuclear receptor retinoid X receptor (RXR) belongs to a nuclear receptor superfamily that modulates diverse functions via homodimerization with itself or several other nuclear receptors, including PPARα. While the activation of PPARα by natural or synthetic agonists regulates the sleep-wake cycle, the role of RXR in the sleep modulation is unknown. Objectives: We investigated the effects of bexarotene (Bexa, a RXR agonist) or UVI 3003 (UVI, a RXR antagonist) on sleep, sleep homeostasis, levels of neurochemical related to sleep modulation, and c-Fos and NeuN expression. Methods: The sleep-wake cycle and sleep homeostasis were analyzed after application of Bexa or UVI. Moreover, we also evaluated whether Bexa or UVI could induce effects on dopamine, serotonin, norepinephrine epinephrine, adenosine, and acetylcholine contents, collected from either the nucleus accumbens or basal forebrain. In addition, c-Fos and NeuN expression in the hypothalamus was determined after Bexa or UVI treatments. Results: Systemic application of Bexa (1 mM, i.p.) attenuated slow-wave sleep and rapid eye movement sleep. In addition, Bexa increased the levels of dopamine, serotonin, norepinephrine epinephrine, adenosine, and acetylcholine sampled from either the nucleus accumbens or basal forebrain. Moreover, Bexa blocked the sleep rebound period after total sleep deprivation, increased in the hypothalamus the expression of c-Fos, and decreased NeuN activity. Remarkably, UVI 3003 (1 mM, i.p.) induced opposite effects in sleep, sleep homeostasis, neurochemicals levels, and c-Fos and NeuN activity. Conclusions: The administration of RXR agonist or antagonist significantly impaired the sleep-wake cycle and exerted effects on the levels of neurochemicals related to sleep modulation. Moreover, Bexa or UVI administration significantly affected c-Fos and NeuN expression in the hypothalamus. Our findings highlight the neurobiological role of RXR on sleep modulation.

Publication metrics

Metrics

SciVal
FWCI
0.09

PlumX, opens in new tab

Captures
25
Social media
1
2